Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | SAFB2 | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-06 |
mRNA | CAPN2 | CTRPv2 | pan-cancer | AAC | -0.18 | 5e-06 |
mRNA | NCOA5 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | CLASRP | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-06 |
mRNA | LRRC59 | CTRPv2 | pan-cancer | AAC | -0.15 | 5e-06 |
mRNA | METTL24 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | CDK13 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | CEP97 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | KLHL25 | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-06 |
mRNA | YLPM1 | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-06 |